Author(s)

Brian A. Boyle, MD, JD

Brian Boyle, MD, Associate Professor, Weill Medical College of Cornell University ; Attending Physician, New York Presbyterian Hospital -- Cornell Medical Center, New York, NY

Disclosures

Disclosure: Brian A. Boyle, MD, JD, has disclosed that he has received grants for educational activities from and served as an advisor or consultant for Gilead Sciences, and has also served on the speaker's bureau and as a consultant for GlaxoSmithKline, Vertex, Abbott, MSD, Bristol-Myers Squibb, Roche, Johnson & Johnson, Tibotec, and Virco. Dr. Boyle does not discuss any investigational or unlabeled uses of commercial products in this activity.

Calvin J. Cohen, MD, MSc

Clinical Instructor, Harvard Medical School, Cambridge, Massachusetts

Disclosures

Disclosure: Calvin J. Cohen, MD, has disclosed that he has received grants for clinical research and grants for educational activities from, as well as served as an advisor or consultant for, Gilead, GlaxoSmithKline, Bristol-Myers Squibb, Abbott, and Boehringer Ingelheim. Dr. Cohen does not discuss any investigational or unlabeled uses of commercial products in this activity.

Michael S. Saag, MD

Professor of Medicine; Director, AIDS Outpatient Clinic, University of Alabama at Birmingham

Disclosures

Disclosure: Michael S. Saag, MD, has disclosed that he has received grants for clinical research and/or has served as an advisor or consultant for Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer/Agouron, Roche, Schering-Plough, Shire Pharmaceutical, Tanx, TherapyEdgem Tibotec/Virco, Trimeris, Vertex, and ViroLogic. Dr. Saag has served on the speaker's bureau for all of the above. Dr. Saag does not discuss any investigational or unlabeled uses of commercial products in this activity.

CME/CE

New Fixed-Dose Combination Treatment Options for HIV Infection: How Do They Compare? An Expert Discussion

Authors: Presenters: Brian A. Boyle, MD, JD, and Calvin J. Cohen, MD; Moderator: Michael S. Saag, MD
THIS ACTIVITY HAS EXPIRED FOR CREDIT

Start Activity

Target Audience and Goal Statement

This activity is intended for physicians, nurses, pharmacists, and other clinical personnel providing frontline care for persons with HIV/AIDS.

The goal of this activity is to provide clinicians involved in the care of patients with HIV/AIDS with an expert discussion of key data and issues concerning the labeling, selection, and use of 2 newly approved fixed-dose combination products for the treatment of HIV infection (tenofovir/emtricitabine and abacavir/lamivudine).

Upon completion of this activity, participants will be able to:

Compare the advantages and disadvantages of once-daily antiretroviral therapy
Review data concerning the safety and efficacy of 2 newly approved fixed-dose combination products for the treatment of HIV infection (tenofovir/emtricitabine and abacavir/lamivudine)
Describe current guidelines, clinical data, and expert recommendations regarding the use of once-daily fixed-dose nucleoside/nucleotide backbones in antiretroviral-naive and -experienced patients

Author(s)

Brian A. Boyle, MD, JD

Brian Boyle, MD, Associate Professor, Weill Medical College of Cornell University ; Attending Physician, New York Presbyterian Hospital -- Cornell Medical Center, New York, NY

Disclosures

Disclosure: Brian A. Boyle, MD, JD, has disclosed that he has received grants for educational activities from and served as an advisor or consultant for Gilead Sciences, and has also served on the speaker's bureau and as a consultant for GlaxoSmithKline, Vertex, Abbott, MSD, Bristol-Myers Squibb, Roche, Johnson & Johnson, Tibotec, and Virco. Dr. Boyle does not discuss any investigational or unlabeled uses of commercial products in this activity.

Calvin J. Cohen, MD, MSc

Clinical Instructor, Harvard Medical School, Cambridge, Massachusetts

Disclosures

Disclosure: Calvin J. Cohen, MD, has disclosed that he has received grants for clinical research and grants for educational activities from, as well as served as an advisor or consultant for, Gilead, GlaxoSmithKline, Bristol-Myers Squibb, Abbott, and Boehringer Ingelheim. Dr. Cohen does not discuss any investigational or unlabeled uses of commercial products in this activity.

Michael S. Saag, MD

Professor of Medicine; Director, AIDS Outpatient Clinic, University of Alabama at Birmingham

Disclosures

Disclosure: Michael S. Saag, MD, has disclosed that he has received grants for clinical research and/or has served as an advisor or consultant for Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer/Agouron, Roche, Schering-Plough, Shire Pharmaceutical, Tanx, TherapyEdgem Tibotec/Virco, Trimeris, Vertex, and ViroLogic. Dr. Saag has served on the speaker's bureau for all of the above. Dr. Saag does not discuss any investigational or unlabeled uses of commercial products in this activity.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape designates this educational activity for a maximum of 1.0 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.

Contact This Provider

For Nurses

Approved for 1.0 contact hour(s) of continuing education for RNs, LPNs, LVNs and NPs. This activity is cosponsored with Medical Education Collaborative, Inc. (MEC) and Medscape. MEC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider Number CEP 12990, for 1.0 contact hour(s).

Approved by the Florida Board of Nursing, Provider Number FBN 2773.

Contact This Provider

For Pharmacists

1.0 contact hour(s) (0.10 CEUs) of credit for pharmacists. Approval of this course for pharmacists is under a cosponsorship agreement between Medical Education Collaborative, Inc. (MEC) and Medscape. MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE # 815-999-04-046-C02

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

The credit that you receive is based on your user profile.

processing....

Welcome and Introduction

[ CLOSE WINDOW ]

Slide 1

Craig Sterritt: Good evening, everyone. I'm Craig Sterritt, Editor of Medscape HIV/AIDS, and I'd like to welcome you to tonight's CME Live expert discussion, entitled "New Fixed-Dose Combination Treatment Options for HIV Infection -- How Do They Compare?"

This CME/CE activity has been made possible by an unrestricted educational grant by Gilead Sciences.

Before we begin, I'd like to take a few moments and go over the format of our program. Dr. Michael Saag will be serving as our expert moderator, and he will frame our discussion with a brief introduction/overview about new fixed-dose treatment options for HIV infection; he will then introduce our 2 speakers, Dr. Brian Boyle and Dr. Cal Cohen, who will be speaking about fixed-dose abacavir/lamivudine and tenofovir/emtricitabine, respectively.

After these 2 product-specific overviews, we'll move on to a moderated discussion of questions and topics relevant to the use and selection of these new treatment options. And, during the course of the program, we'll pause briefly to ask and to then share the results of 2 audience polling questions.

We'll then conclude with a Q&A session, so we invite our participants to send us questions by using the interface box at the bottom left of your screen. Submit a question at any time during the presentation.

And, finally, for those of you who wish to obtain CME or CE credit for this activity, just follow the link that appears in the pop-up window at the very end of the program. This will take you to the post-test.
[ CLOSE WINDOW ]

Slide 2

Page 1 of 13

Moderator's Introduction and Overview

Faculty and Disclosures

Author(s)

Brian A. Boyle, MD, JD

Calvin J. Cohen, MD, MSc

Michael S. Saag, MD

CME/CE

New Fixed-Dose Combination Treatment Options for HIV Infection: How Do They Compare? An Expert Discussion

Target Audience and Goal Statement

Author(s)

Brian A. Boyle, MD, JD

Calvin J. Cohen, MD, MSc

Michael S. Saag, MD

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

New Fixed-Dose Combination Treatment Options for HIV Infection: How Do They Compare? An Expert Discussion

Welcome and Introduction

Slide 1

Slide 2